AMGEN INC (AMGN) Stock Price, Forecast & Analysis
USA - NASDAQ:AMGN - US0311621009 - Common Stock
AMGN Key Statistics, Chart & Performance
The current stock price of AMGN is 336.74 USD. In the past month the price increased by 12.69%. In the past year, price increased by 18.73%.
AMGN Latest News, Press Relases and Analysis
AMGN Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.59 | 410.48B | ||
| GILD | GILEAD SCIENCES INC | 15.26 | 155.13B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 25.18 | 112.08B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.41 | 73.50B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 880.71 | 58.88B | ||
| INSM | INSMED INC | N/A | 40.84B | ||
| NTRA | NATERA INC | N/A | 28.04B | ||
| BIIB | BIOGEN INC | 10.01 | 24.56B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.67 | 21.10B | ||
| INCY | INCYTE CORP | 16.22 | 20.34B | ||
| NBIX | NEUROCRINE BIOSCIENCES INC | 34.66 | 14.37B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 13.39B |
Related stock screener links
About AMGN
Company Profile
Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. The company is headquartered in Thousand Oaks, California and currently employs 28,000 full-time employees. The company discovers, develops, manufactures and delivers medicines for the toughest diseases. The company focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve people’s lives. The company operates in the human therapeutics segment. Its marketed products portfolio includes EPOGEN (epoetin alfa); Aranesp (darbepoetin alfa); Parsabiv (etelcalcetide); Neulasta (pegfilgrastim); KANJINTI (trastuzumab-anns); Otezla; BLINCYTO (blinatumomab); ACTIMMUNE (interferon gamma-1b); Neulasta (pegfilgrastim); Sensipar/Mimpara (cinacalcet); Prolia (denosumab); ENBREL; QUINSAIR (levofloxacin); Repatha (evolocumab) and others. The company markets ENBREL, a tumor necrosis factor blocker, in the United States and Canada. The company markets Otezla, a small molecule that inhibits phosphodiesterase 4, in many countries around the world. The company markets Repatha, a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, in many countries around the world.
Company Info
AMGEN INC
One Amgen Center Drive
Thousand Oaks CALIFORNIA 91320 US
CEO: Robert A. Bradway
Employees: 28000
Phone: 18054471000
AMGEN INC / AMGN FAQ
Can you describe the business of AMGEN INC?
Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. The company is headquartered in Thousand Oaks, California and currently employs 28,000 full-time employees. The company discovers, develops, manufactures and delivers medicines for the toughest diseases. The company focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve people’s lives. The company operates in the human therapeutics segment. Its marketed products portfolio includes EPOGEN (epoetin alfa); Aranesp (darbepoetin alfa); Parsabiv (etelcalcetide); Neulasta (pegfilgrastim); KANJINTI (trastuzumab-anns); Otezla; BLINCYTO (blinatumomab); ACTIMMUNE (interferon gamma-1b); Neulasta (pegfilgrastim); Sensipar/Mimpara (cinacalcet); Prolia (denosumab); ENBREL; QUINSAIR (levofloxacin); Repatha (evolocumab) and others. The company markets ENBREL, a tumor necrosis factor blocker, in the United States and Canada. The company markets Otezla, a small molecule that inhibits phosphodiesterase 4, in many countries around the world. The company markets Repatha, a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, in many countries around the world.
Can you provide the latest stock price for AMGEN INC?
The current stock price of AMGN is 336.74 USD. The price increased by 0.22% in the last trading session.
Does AMGN stock pay dividends?
AMGEN INC (AMGN) has a dividend yield of 2.83%. The yearly dividend amount is currently 9.01.
What is the ChartMill rating of AMGEN INC stock?
AMGN has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 5 out of 10.
Which stock exchange lists AMGN stock?
AMGN stock is listed on the Nasdaq exchange.
What sector and industry does AMGEN INC belong to?
AMGEN INC (AMGN) operates in the Health Care sector and the Biotechnology industry.
How is the valuation of AMGEN INC (AMGN) based on its PE ratio?
The PE ratio for AMGEN INC (AMGN) is 15.4. This is based on the reported non-GAAP earnings per share of 21.87 and the current share price of 336.74 USD.
AMGN Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to AMGN. When comparing the yearly performance of all stocks, AMGN is one of the better performing stocks in the market, outperforming 80.67% of all stocks.
AMGN Fundamental Analysis
ChartMill assigns a fundamental rating of 5 / 10 to AMGN. AMGN has an excellent profitability rating, but there are concerns on its financial health.
AMGN Financial Highlights
Over the last trailing twelve months AMGN reported a non-GAAP Earnings per Share(EPS) of 21.87. The EPS increased by 13.79% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 19.47% | ||
| ROA | 7.77% | ||
| ROE | 72.82% | ||
| Debt/Equity | 5.45 |
AMGN Forecast & Estimates
40 analysts have analysed AMGN and the average price target is 319.63 USD. This implies a price decrease of -5.08% is expected in the next year compared to the current price of 336.74.
For the next year, analysts expect an EPS growth of 8.22% and a revenue growth 7.43% for AMGN